Shaohong Luo
Overview
Explore the profile of Shaohong Luo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamal A, Li B, Solayman A, Luo S, Kinloch I, Zheng L, et al.
Nanoscale Horiz
. 2024 Dec;
10(3):512-536.
PMID: 39711209
Two-dimensional (2D) materials are materials with a thickness of one or a few atoms with intriguing electrical, chemical, optical, electrochemical, and mechanical properties. Therefore, they are deemed candidates for ubiquitous...
2.
Lai S, Luo S, Lin S, Huang X, Wang X, Xu X, et al.
Pract Radiat Oncol
. 2024 Aug;
15(1):e10-e20.
PMID: 39216726
Background: Bevacizumab has been demonstrated to have superior efficacy in the treatment of cerebral radiation necrosis (CRN), but its high cost may exacerbate the disease burden. This study aimed to...
3.
Lai S, Luo S, Huang Q, Lin S, Huang X, Xue H, et al.
Pharmacogenomics
. 2024 Jun;
25(5-6):249-257.
PMID: 38884946
To estimate the cost-effectiveness of zolbetuximab plus capecitabine/oxaliplatin (CAPOX) in CLDN18.2-positive, negative, mG/GEJ adenocarcinoma from the perspective of Chinese payers. A partitioned survival model was developed to assess the costs,...
4.
Luo S, Lai S, Wu Y, Hong J, Lin D, Lin S, et al.
Strahlenther Onkol
. 2024 Jun;
200(9):805-814.
PMID: 38829437
Background: Bevacizumab shows superior efficacy in cerebral radiation necrosis (CRN) therapy, but its economic burden remains heavy due to the high drug price. This study aims to evaluate the cost-effectiveness...
5.
Liao X, Wu Y, Lin D, Gu D, Luo S, Huang X, et al.
J Obstet Gynaecol Res
. 2024 Mar;
50(5):881-889.
PMID: 38485235
Purpose: To investigate the cost-effectiveness of lenvatinib plus pembrolizumab (LP) compared to chemotherapy as a second-line treatment for advanced endometrial cancer (EC) from the United States and Chinese payers' perspective....
6.
Xie C, Huang X, Lin D, Huang X, Lin S, Luo S, et al.
Prev Med
. 2023 Nov;
177:107775.
PMID: 37951546
Objectives: This study provided estimates of cancer incidence rate and onset age by Socio-demographic Index (SDI) regions and gender from 2020 to 2040, aiming to clarify the long-term patterns of...
7.
Luo S, Lin D, Lai S, Lin S, Zhong L, Huang X, et al.
Nutrition
. 2023 Nov;
117:112225.
PMID: 37951049
Objective: The aim of this study was to estimate the effect of dietary consumption on cancer burden and formulate an effective solution. Methods: Dietary consumption, number of cancer deaths, disability-adjusted...
8.
Ahmed S, Li B, Luo S, Liao K
ACS Appl Mater Interfaces
. 2023 Oct;
15(42):49458-49467.
PMID: 37844286
MXene, as a novel two-dimensional (2D) material, has unique inherent features such as lightweight, flexibility, high electrical conductivity, customizable surface chemistry, and facile solution processability. However, utilizing MXene (TiCT) films...
9.
Luo S, Xie C, Lin N, Lin D, Gu D, Lin S, et al.
Melanoma Res
. 2023 Aug;
33(6):525-531.
PMID: 37650713
The normative regimens recommendations for treating metastatic uveal melanoma (mUM) are absent in the US. Recently, a phase III randomized clinical trial revealed that tebentafusp yielded a conspicuously longer overall...
10.
Huang X, Lin D, Lin S, Luo S, Huang X, Deng Y, et al.
Clin Breast Cancer
. 2023 Apr;
23(5):508-518.
PMID: 37085377
Background: Recently, the DESTINY-Breast04 trial revealed that trastuzumab deruxtecan (T-DXd) significantly prolonged overall survival in patients with human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (MBC). Considering the...